Torrent Pharmaceuticals Ltd

AI
Torrent Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Torrent Pharmaceuticals Ltd

₹ 4,772 0.00%
06 Oct - close price
torrentpharma.com BSE: 500420 NSE: TORNTPHARM F&O
About

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1]

It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]

Key Points

Product Segment FY26:
a) Branded Generics (74%):[1]
The company’s branded generics business
focuses on the manufacturing pharmaceutical products under its brand names catering
to various therapeutic segments including cardiovascular, central nervous system, gastrointestinal, vitamin mineral nutrients, dermatology, diabetes, pain management
and gynecology. Its branded generic medicines
are marketed in key regions including India
and Brazil.[2]
b) Generics (26%):
The generics segment specializes in manufacturing and supplying generic pharmaceutical products, particularly in the markets where patent exclusivity has expired or regulatory approval allows for the production of generic versions of branded drugs. This segment focuses on specific markets, including emerging and regulated ones like the US, Europe, etc. [3]

Website BSE NSE F&O
  • Market Cap ₹ 1,81,512 Cr.
  • Current Price ₹ 4,772
  • High / Low ₹ 5,250 / 3,480
  • Stock P/E 81.4
  • Book Value ₹ 248
  • Dividend Yield 0.80 %
  • ROCE 15.2 %
  • ROE 27.4 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • Company has been maintaining a healthy dividend payout of 57.8%

Cons

  • Stock is trading at 19.2 times its book value
  • Promoter holding has decreased over last quarter: -7.53%
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty Next 50

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
2,591 2,660 2,732 2,745 2,859 2,889 2,809 2,959 3,178 3,302 3,303 4,197 4,921
1,800 1,835 1,863 1,862 1,955 1,950 1,895 1,995 2,146 2,219 2,215 2,841 3,257
Operating Profit 791 825 869 883 904 939 914 964 1,032 1,083 1,088 1,356 1,664
OPM % 31% 31% 32% 32% 32% 32% 33% 33% 32% 33% 33% 32% 34%
34 26 55 31 24 -16 33 -42 -37 -40 -23 -83 -33
Interest 103 91 80 80 75 64 57 56 56 48 45 236 305
Depreciation 191 201 213 203 197 198 199 201 201 204 206 508 593
Profit before tax 531 559 631 631 656 661 691 665 738 791 814 529 733
Tax % 29% 31% 30% 29% 30% 31% 27% 25% 26% 25% 22% 31% 23%
378 386 443 449 457 453 503 498 548 591 635 364 566
EPS in Rs 11.17 11.41 13.09 13.27 13.50 13.38 14.86 14.71 16.19 17.46 18.76 10.76 16.72
Raw PDF
Upcoming result date: 23 October 2026

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
4,636 6,687 5,816 5,950 7,673 7,939 8,005 8,508 9,620 10,728 11,516 13,980 15,723
3,616 3,954 4,438 4,601 5,690 5,769 5,524 6,077 6,778 7,360 7,795 9,421 10,532
Operating Profit 1,020 2,733 1,377 1,349 1,983 2,170 2,480 2,431 2,842 3,368 3,721 4,558 5,191
OPM % 22% 41% 24% 23% 26% 27% 31% 29% 30% 31% 32% 33% 33%
286 32 223 299 -300 121 57 -288 45 146 -1 -182 -179
Interest 175 184 206 308 504 451 353 255 333 354 252 385 634
Depreciation 191 238 307 409 618 654 658 662 707 808 795 1,119 1,511
Profit before tax 940 2,343 1,088 931 562 1,187 1,526 1,226 1,847 2,352 2,673 2,872 2,867
Tax % 20% 26% 14% 27% 22% 14% 18% 37% 33% 30% 28% 26%
751 1,733 934 678 436 1,025 1,252 777 1,245 1,656 1,911 2,138 2,156
EPS in Rs 22.19 51.22 27.59 20.04 12.89 30.28 36.99 22.97 36.79 48.94 56.47 63.92 63.70
Dividend Payout % 25% 34% 25% 35% 66% 53% 47% 105% 60% 57% 57% 59%
Compounded Sales Growth
10 Years: 8%
5 Years: 12%
3 Years: 13%
TTM: 33%
Compounded Profit Growth
10 Years: 2%
5 Years: 12%
3 Years: 22%
TTM: 10%
Stock Price CAGR
10 Years: 19%
5 Years: 25%
3 Years: 36%
1 Year: 35%
Return on Equity
10 Years: 22%
5 Years: 24%
3 Years: 26%
Last Year: 27%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 85 85 85 85 85 85 85 85 169 169 169 169
Reserves 2,406 3,409 4,266 4,538 4,640 4,739 5,753 5,868 6,029 6,687 7,421 8,219
2,740 2,352 2,510 6,462 6,038 5,784 4,874 4,070 5,369 4,022 3,202 15,026
2,589 3,040 2,740 3,159 3,351 3,402 3,363 2,884 3,043 3,627 3,603 20,200
Total Liabilities 7,820 8,886 9,601 14,243 14,113 14,010 14,075 12,906 14,610 14,505 14,396 43,614
2,833 2,859 3,688 7,855 7,748 7,533 7,065 6,423 8,121 8,138 7,947 33,191
CWIP 678 1,042 519 647 617 712 889 630 765 361 478 641
Investments 298 780 804 492 353 2 181 226 199 173 156 948
4,011 4,206 4,589 5,249 5,395 5,763 5,940 5,628 5,524 5,834 5,815 8,833
Total Assets 7,820 8,886 9,601 14,243 14,113 14,010 14,075 12,906 14,610 14,505 14,396 43,614

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
810 2,742 1,009 894 1,798 1,393 2,005 1,803 2,368 3,266 2,585 3,023
-2,113 -869 -798 -4,677 -246 229 -444 -196 -2,335 -160 -549 -12,630
1,212 -1,435 -193 3,417 -1,314 -1,549 -1,651 -1,781 77 -2,780 -2,298 10,151
Net Cash Flow -90 437 18 -366 238 73 -89 -174 110 327 -262 544
Free Cash Flow 574 2,150 523 105 1,138 990 1,671 1,607 1,953 2,967 1,991 2,386
CFO/OP 85% 121% 101% 87% 105% 77% 88% 91% 97% 112% 86% 84%

Ratios

Consolidated / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 125 79 60 77 68 76 69 70 74 63 59 79
Inventory Days 275 314 318 429 318 362 456 368 298 310 334 338
Days Payable 472 523 356 447 345 345 351 250 224 284 239 254
Cash Conversion Cycle -71 -130 21 59 42 93 174 188 147 89 154 163
Working Capital Days 29 -1 28 -80 -62 -52 -5 7 -33 -27 7 -26
ROCE % 27% 48% 19% 13% 13% 15% 17% 19% 20% 23% 27% 15%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cumulative ANDA Approvals (US)
approvals ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Germany Generics Market Share
% of generics market ・Standalone data
India IPM Rank (Position)
rank (lower is better) ・Standalone data
R&D Expenditure as % of Revenue
% of revenue
India Field Force (Medical Representatives)
MRs ・Standalone data
Brazil Field Force (Medical Representatives)
MRs ・Standalone data
Branded Business Share of Revenue
% of revenue
Brazil IQVIA/Secondary Sales Growth
% growth YoY ・Standalone data
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Jul 2026
71.25% 71.25% 71.25% 71.25% 68.31% 68.31% 68.31% 68.31% 68.31% 68.31% 68.31% 60.78%
14.08% 14.14% 14.22% 14.46% 16.17% 16.31% 16.09% 15.92% 16.13% 16.18% 15.44% 17.97%
7.11% 7.15% 7.17% 6.98% 8.25% 8.25% 8.54% 9.17% 9.05% 8.96% 9.73% 12.77%
0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.10% 0.00% 0.10% 0.09%
7.46% 7.34% 7.25% 7.21% 7.17% 7.02% 6.93% 6.47% 6.41% 6.55% 6.42% 8.39%
No. of Shareholders 69,11771,15474,76579,84885,03586,00581,85678,22676,21483,81185,7761,40,599

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls